Altimmune’s (ALT) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of Altimmune (NASDAQ:ALT) in a report published on Friday,Weiss Ratings reports.

A number of other equities analysts also recently weighed in on the stock. UBS Group cut their price target on shares of Altimmune from $26.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. The Goldman Sachs Group upgraded shares of Altimmune to a “strong sell” rating in a research note on Thursday, July 10th. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a research report on Monday, October 20th. B. Riley lowered their price target on shares of Altimmune from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Finally, Wall Street Zen upgraded Altimmune from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Altimmune presently has an average rating of “Hold” and a consensus target price of $17.40.

Altimmune Trading Down 0.3%

NASDAQ:ALT opened at $3.95 on Friday. Altimmune has a 52 week low of $2.90 and a 52 week high of $11.16. The firm has a 50-day moving average price of $3.79 and a two-hundred day moving average price of $4.57. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44. The firm has a market cap of $348.63 million, a price-to-earnings ratio of -3.35 and a beta of 0.07.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%.The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. On average, equities analysts expect that Altimmune will post -1.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Concurrent Investment Advisors LLC bought a new stake in Altimmune during the 1st quarter valued at $108,000. Deutsche Bank AG grew its position in shares of Altimmune by 3.9% in the first quarter. Deutsche Bank AG now owns 79,851 shares of the company’s stock valued at $399,000 after purchasing an additional 3,026 shares in the last quarter. PFG Investments LLC grew its position in shares of Altimmune by 31.6% in the first quarter. PFG Investments LLC now owns 17,500 shares of the company’s stock valued at $88,000 after purchasing an additional 4,200 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Altimmune by 214.2% during the 1st quarter. GAMMA Investing LLC now owns 6,745 shares of the company’s stock valued at $34,000 after purchasing an additional 4,598 shares during the period. Finally, Hsbc Holdings PLC purchased a new stake in Altimmune during the 1st quarter worth about $349,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.